CN1357331A - Suppository for controlling sexual spread of AIDS - Google Patents
Suppository for controlling sexual spread of AIDS Download PDFInfo
- Publication number
- CN1357331A CN1357331A CN 01138326 CN01138326A CN1357331A CN 1357331 A CN1357331 A CN 1357331A CN 01138326 CN01138326 CN 01138326 CN 01138326 A CN01138326 A CN 01138326A CN 1357331 A CN1357331 A CN 1357331A
- Authority
- CN
- China
- Prior art keywords
- suppository
- milligrams
- aids
- virus
- miconazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The suppository for controlling sexual spread of AIDS contains Zidovudine and substrate and each grain of the suppository may also contains Aciclovir 0-500 mg, Amphotercin 0-50 mg, Miconazole 0-300 mg, surfactant 0-100 mg and deodorant 0-100 mg. It is applied locally to urogenital system and this results in less toxic side effect and high biological utilization. Its Aciclovir is converted in vivo into triphophate compound to interfere the duplication of herpes simple xvirus DNA and to inhibit herpes virus, cytomegalo virus and EB virus; Amphotercin is used for treating vaginalmucous membrane infection; and Miconazole has broad-spectrum antifungal function.
Description
Technical field
The invention belongs to pharmaceutical sanitary field, is the approach that spreads through sex intercourse at acquired immune deficiency syndrome (AIDS), a kind of suppository of treatment acquired immune deficiency syndrome (AIDS) and part urinary tract infection.
Background technology
Calendar year 2001, State Council assigns relevant document " China contains and prevents and treats the acquired immune deficiency syndrome (AIDS) action plan " and points out that " form of China's acquired immune deficiency syndrome (AIDS) prevention and treatment of venereal diseases work is still very severe, and the acquired immune deficiency syndrome (AIDS) sexually transmitted disease (STD) is popular to present a rapidly rising trend." the present number of the infected of China surpassed 600,000, estimates according to the relevant expert, if increase progressively with annual 30% ratio, will reach 1,000 ten thousand people to China's HIV sufferers in 2010.Preventing and treating acquired immune deficiency syndrome (AIDS) is the major issue that is related to national economy.
Acquired immune deficiency syndrome (AIDS) has three kinds of routes of transmission: blood propagation, spread through sex intercourse, mother-to-baby transmission.Studies show that it is the main cause that great majority infect in the present world wide that acquired immune deficiency syndrome (AIDS) is propagated through sexual behaviour.In China, be mainly blood propagation at present.But after severe policy of hitting illegal blood collecting and supplying is put into effect, the blood propagation approach of acquired immune deficiency syndrome (AIDS) will be effectively controlled, and spreading through sex intercourse to become main path, and the number that infects by this approach will reach a peak.
Zidovudine (AZT) is a kind ofly to be used for the treatment of the important drugs of HIV (human immunodeficiency virus) infection in the U.S., has another name called azidothymidine AZT, is a kind of nucleoside medicine, can suppress duplicating of reverse transcriptase and HIV.Its existing main application method has two kinds: administration of injection whole body and oral tablet.The former is stronger to the side effect of hemopoietic function of bone marrow; Latter's degree of absorbing is low, and is big to hepatorenal damage.The present invention promptly is at the problems referred to above, utilizes the suppository topical, mainly acts on genitourinary system, and toxic and side effects is little, the bioavailability height.
In recent years the new development to acquired immune deficiency syndrome (AIDS) research shows to suffer from the individuality of sexually transmitted disease (STD), as genital herpes virus the infected, various fungal infection of vagina person, and dangerous higher by HIV (human immunodeficiency virus) infection.Because HIV (human immunodeficiency virus) between sex partner propagation difference and the genitals juice in the varying level of infected cell much relations are arranged, have the inflammatory cell that comprises virus infected cell in a large number in these people's the genitals juice.The present invention has the therapeutic effect to common urinary tract infection concurrently, and assosting effect is played in the control of sexual spread of AIDS.
Summary of the invention
It is little that problem to be solved by this invention provides a kind of toxic and side effects, the suppository that the higher control AIDS of bioavailability spreads through sex intercourse.
Technical scheme provided by the present invention is: the suppository that a kind of control AIDS spreads through sex intercourse, contain zidovudine and suppository base.
Every suppository contains 50-500 milligram zidovudine.
Every suppository also can contain 0-500 milligram acycloguanosine, 0-50 milligram amphotericin, 0-300 milligram miconazole, 0-100 milligram surfactant, 0-100 milligram deodorizer.
Above-mentioned suppository base can adopt any vaginal application substrate easily, as cupu oil, tristerin, sugared gel, Polyethylene Glycol, palm kernel wet goods.
In order vaginal mucosa to be absorbed the drug better can in suppository, add surfactant such as glycol ester, glycerol.
The present invention also can add deodorizer such as chlorine phenanthrene as required in suppository.
The present invention utilizes the suppository topical, mainly acts on genitourinary system, thereby toxic and side effects is little, the bioavailability height.Because acycloguanosine (ACV) is converted into the triphosphoric acid chemical compound in vivo, disturb duplicating of herpes simplex virus dna, herpes I, II type virus, varicella zoster virus, cytomegalovirus and Epstein-Barr virus all there are inhibitory action; Amphotericin is anti-deep fungal infection medicine, is used for the treatment of vaginal mucosa and infects; Miconazole is the broad-spectrum antifungal medicine, can adopt miconazole nitrate.
The specific embodiment
Embodiment 1 suppository of the present invention is packaged as 2400 milligrams every, is a unit.Per unit contains 500 milligrams of zidovudines, 80 milligrams in surfactant, 100 milligrams of deodorizer, and all the other are suppository base.The effective ingredient zidovudine is mixed in fused suppository base cupu oil with surfactant glycol ester, deodorizer chlorine phenanthrene, and the mixture that forms is poured in the refrigerative model, promptly get required suppository.
Embodiment 2 suppositorys of the present invention are packaged as 2400 milligrams every, are a unit.Per unit contains 300 milligrams of zidovudines, 500 milligrams of acycloguanosine, 100 milligrams in surfactant, 20 milligrams of deodorizer, and all the other are suppository base.Effective ingredient zidovudine, acycloguanosine are mixed in fused suppository base tristerin with surfactant glycerine ester, deodorizer chlorine phenanthrene, and the mixture that forms is poured in the refrigerative model, promptly get required suppository.
Embodiment 3 suppositorys of the present invention are packaged as 2400 milligrams every, are a unit.Per unit contains 200 milligrams of zidovudines, 100 milligrams of acycloguanosine, 300 milligrams of miconazoles, 10 milligrams in surfactant, 100 milligrams of deodorizer, and all the other are suppository base.Effective ingredient zidovudine, acycloguanosine, miconazole are mixed in fused suppository base sugar gel with surfactant glycol ester, deodorizer chlorine phenanthrene, and the mixture that forms is poured in the refrigerative model, promptly get required suppository.
Embodiment 4 suppositorys of the present invention are packaged as 2400 milligrams every, are a unit.Per unit contains 150 milligrams of zidovudines, 300 milligrams of acycloguanosine, 60 milligrams of miconazoles, 10 milligrams of amphotericins, 50 milligrams in surfactant, and all the other are suppository base.Effective ingredient zidovudine, acycloguanosine, miconazole, amphotericin are mixed in fused suppository base Polyethylene Glycol with the surfactant glycerine ester, and the mixture that forms is poured in the refrigerative model, promptly get required suppository.
Embodiment 5 suppositorys of the present invention are packaged as 2400 milligrams every, are a unit.Per unit contains 400 milligrams of zidovudines, 100 milligrams of acycloguanosine, 50 milligrams of amphotericins, and all the other are suppository base.Effective ingredient zidovudine, acycloguanosine, amphotericin are mixed in fused suppository base sugar gel, and the mixture that forms is poured in the refrigerative model, promptly get required suppository.
Embodiment 6 suppositorys of the present invention are packaged as 2400 milligrams every, are a unit.Per unit contains 450 milligrams of zidovudines, 260 milligrams of miconazoles, 80 milligrams of deodorizer, and all the other are suppository base.Effective ingredient zidovudine, miconazole are mixed in fused suppository base Polyethylene Glycol with deodorizer chlorine phenanthrene, and the mixture that forms is poured in the refrigerative model, promptly get required suppository.
Embodiment 7 suppositorys of the present invention are packaged as 2400 milligrams every, are a unit.Per unit contains 250 milligrams of zidovudines, 30 milligrams of amphotericins, 70 milligrams in surfactant, 50 milligrams of deodorizer, and all the other are suppository base.Effective ingredient zidovudine, amphotericin are mixed in fused suppository base palm-kernel oil with surfactant glycerine ester and deodorizer chlorine phenanthrene, and the mixture that forms is poured in the refrigerative model, promptly get required suppository.
Claims (4)
1. the suppository that control AIDS spreads through sex intercourse contains zidovudine and suppository base.
2. suppository according to claim 1 is characterized in that: every suppository contains 50-500 milligram zidovudine.
3. suppository according to claim 1 and 2 is characterized in that: every suppository contains 0-500 milligram acycloguanosine, 0-50 milligram amphotericin, 0-300 milligram miconazole.
4. suppository according to claim 3 is characterized in that: every suppository contains 0-100 milligram surfactant, 0-100 restrains deodorizer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01138326 CN1357331A (en) | 2001-12-20 | 2001-12-20 | Suppository for controlling sexual spread of AIDS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01138326 CN1357331A (en) | 2001-12-20 | 2001-12-20 | Suppository for controlling sexual spread of AIDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1357331A true CN1357331A (en) | 2002-07-10 |
Family
ID=4674532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01138326 Pending CN1357331A (en) | 2001-12-20 | 2001-12-20 | Suppository for controlling sexual spread of AIDS |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1357331A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178938A (en) * | 2011-04-20 | 2011-09-14 | 中国水产科学研究院黄海水产研究所 | Marine lysozyme suppository and preparation method thereof |
| CN104606215A (en) * | 2014-12-31 | 2015-05-13 | 中国医学科学院病原生物学研究所 | Drug for inhibiting enterovirus 71 |
-
2001
- 2001-12-20 CN CN 01138326 patent/CN1357331A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178938A (en) * | 2011-04-20 | 2011-09-14 | 中国水产科学研究院黄海水产研究所 | Marine lysozyme suppository and preparation method thereof |
| CN104606215A (en) * | 2014-12-31 | 2015-05-13 | 中国医学科学院病原生物学研究所 | Drug for inhibiting enterovirus 71 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1177594C (en) | Formulation for use in prevention of pathogen induced diseases including HIV and HSV | |
| US4285934A (en) | Treatment for herpes virus | |
| US4381296A (en) | Treatment for herpes virus | |
| US6500460B1 (en) | Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations into mucosal cavities | |
| Hellberg et al. | Self-treatment of female external genital warts with 0.5% Podophyllotoxin cream (Condyline®) vs weekly applications of 20% Podophyllin Solution | |
| EP0077063B1 (en) | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis | |
| Madersbacher et al. | Intravesical Application of Oxybutynine: Mode of Action in Controlling Detrusor Hyperref lexia | |
| KR102591220B1 (en) | Compositions and medical devices comprising acetylsalicylic acid for the treatment of human papillomavirus skin infections | |
| Klutke et al. | Interferon as an adjuvant treatment for genital condyloma acuminatum | |
| Porras et al. | Update on cutaneous manifestations of HIV infection | |
| BAKER et al. | Topical podofilox for the treatment of condylomata acuminata in women | |
| US6150400A (en) | Method for treating vulvar vestibulitis | |
| JP2002509540A (en) | Pharmaceutical composition containing aldose reductase inhibitor and ACE inhibitor | |
| US20140011838A1 (en) | Compositions and methods for treating warts associated with viral infections | |
| CN101269058B (en) | Spraying agent containing diclofenac acid and uses thereof | |
| CN1357331A (en) | Suppository for controlling sexual spread of AIDS | |
| Krebs | The use of topical 5-fluorouracil in the treatment of genital condylomas | |
| US6355226B1 (en) | Topical treatment of skin disease and eye afflictions | |
| US4427684A (en) | Treatment and prevention of infection with herpes simplex and related viruses | |
| US20070032558A1 (en) | Method of treating herpes viral infections using a halogenated hydrocarbon composition | |
| CN102652016A (en) | Mucoadhesive buccal tablets for the treatment of orofacial herpes | |
| EP2629772B1 (en) | Ivermectin for use in the treatment of hemorrhoids | |
| CN109350663A (en) | A kind of pharmaceutical composition and preparation method thereof for treating puerperal infection | |
| US20140011837A1 (en) | Compositions and methods for treating warts associated with viral infections | |
| CN102727634A (en) | Traditional Chinese medicine composition for treating gynecological disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |